Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TPH1 | P17752 | 1/20 | 0.54 |
| ▸ | GRB2 | P62993 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382864 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL14693775 | 0.96 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL14693706 | 0.96 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL2225062 | 0.89 | SLC7A5 (0.76) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7185418 | 0.89 | SLC7A5 (0.53) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL10666936 | 0.87 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.86 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| 4-Formylpyridine SCHEMBL25419945 | 0.85 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28317415 | 0.84 | SLC7A5 (0.63) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL3360096 | 0.84 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122849-A1 | METHODS FOR MAKING A GENETICALLY ENGINEERED ORGANISM EXCLUSIVELY COMMUNICATE TO OR RELY ON ANOTHER ENGINEERED ORGANISM | UNIVERSITY OF DELAWARE (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-115698307-A | Split inteins and uses thereof | 移接生物有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114787159-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-111936494-A | Substituted hydro-pyrido-azines as sodium channel inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | KRANTZ ALEXANDER (US) | 2020-03-26 | — | — | US | disclosed |
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | Krantz, Alexander (US) | 2019-06-25 | — | — | US | disclosed |
| EP-3413921-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | Krantz, Alexander (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20170275331-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | KRANTZ ALEXANDER (US) | 2017-09-28 | — | — | US | disclosed |
| US-20100061936-A1 | UNNATURAL AMINO ACIDS CAPABLE OF COVALENTLY MODIFYING PROTEIN PHOSPHATASES AND THEIR USE AS GENERAL AND SPECIFIC INHIBITORS AND PROBES | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY | 2010-03-11 | — | — | US | disclosed |
| US-7538182-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| CN-1314682-C | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | ELAN PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7129327-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| CN-1656090-A | Inhibition by alpha4Integrin-mediated leukocyte adhesion heterocyclic compounds | ELAN PHARM INC (US) | 2005-08-17 | — | — | CN | disclosed |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6673347-B1 | CONJUGATED TO POLYMER VIA SCHIFF BASE, HYDRAZONE, OXIME, OR AZOMETHINE COMPOUND; DIAGNOSING TUMORS AND METASTASIS | GRYPHON THERAPEUTICS | 2004-01-06 | — | — | US | disclosed |
| EP-0243929-B1 | Polypeptide and protein derivatives and process for their preparation | OFFORD ROBIN EWART (CH) | 1995-09-27 | — | — | EP | disclosed |
| EP-0243929-A2 | Polypeptide and protein derivatives and process for their preparation | Offord, Robin Ewart (CH) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | MYCBP, FABP3, STUB1 | SLC7A5 955/4885PTGS1 4587/4885ALPI 3809/4885 |
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | HDGFL3, HCCS, HDGF | SLC7A5 1365/4885PTGS1 2395/4885ALPI 4019/4885 |
| US-20170275331-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | MYCBP, FABP3, STUB1 | SLC7A5 955/4885PTGS1 4587/4885ALPI 3809/4885 |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | MYCBP, FABP3, STUB1 | SLC7A5 955/4885PTGS1 4587/4885ALPI 3809/4885 |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | INSRR, GIPR, HM13 | SLC7A5 1133/4885PTGS1 3071/4885ALPI 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.